Q2 Earnings Estimate for Senseonics Issued By HC Wainwright

Senseonics Holdings, Inc. (NYSE:SENS - Free Report) - HC Wainwright issued their Q2 2025 EPS estimates for shares of Senseonics in a research note issued to investors on Monday, June 2nd. HC Wainwright analyst S. Lee expects that the company will post earnings per share of ($0.02) for the quarter. HC Wainwright currently has a "Buy" rating and a $1.10 price target on the stock. The consensus estimate for Senseonics' current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Senseonics' Q3 2025 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.06) EPS, FY2028 earnings at ($0.01) EPS and FY2029 earnings at $0.01 EPS.

SENS has been the subject of a number of other reports. Wall Street Zen raised Senseonics to a "sell" rating in a research report on Monday, May 12th. Mizuho started coverage on Senseonics in a report on Thursday, April 10th. They issued an "outperform" rating and a $2.00 target price for the company.

Senseonics Trading Down 0.3%

Shares of NYSE:SENS traded down $0.00 during midday trading on Tuesday, reaching $0.53. The company's stock had a trading volume of 5,589,389 shares, compared to its average volume of 6,800,518. Senseonics has a fifty-two week low of $0.25 and a fifty-two week high of $1.40. The firm has a market capitalization of $344.71 million, a price-to-earnings ratio of -4.05 and a beta of 0.97. The firm has a 50 day moving average price of $0.60 and a two-hundred day moving average price of $0.66. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47.

Senseonics (NYSE:SENS - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.09). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same period last year, the company earned ($0.07) EPS.

Institutional Trading of Senseonics

A number of large investors have recently bought and sold shares of SENS. Charles Schwab Investment Management Inc. lifted its position in shares of Senseonics by 9.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,339,698 shares of the company's stock worth $1,748,000 after acquiring an additional 274,842 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Senseonics in the fourth quarter worth $26,000. HighTower Advisors LLC purchased a new stake in Senseonics during the fourth quarter valued at about $32,000. Virtu Financial LLC purchased a new stake in Senseonics during the fourth quarter valued at about $148,000. Finally, Geode Capital Management LLC raised its position in Senseonics by 9.7% during the fourth quarter. Geode Capital Management LLC now owns 6,405,100 shares of the company's stock valued at $3,354,000 after purchasing an additional 566,704 shares in the last quarter. 12.36% of the stock is owned by hedge funds and other institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.